 Anavex Life Sciences Corporation conducts clinical trials for its small Anavex 2-73 blarcamesine and Anavex 3-71 AF710B molecules. The biotech has a rich development pipeline aimed at neurodegenerative and neuro-developmental disorders, such as Parkinsons, Alzheimers and Rett diseases. 